Melanin and Dermal Uptake of Thirdhand Cigarette Smoke
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 25, 2023
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Melanin and Dermal Uptake of Thirdhand Cigarette Smoke," aims to explore how the pigment in our skin, known as melanin, affects the way our bodies absorb and retain nicotine, which is found in cigarette smoke. The researchers believe that people with higher levels of melanin may take in less nicotine and hold onto it for a shorter time. This study is looking for healthy adult nonsmokers aged 18 to 50 who meet specific skin and health criteria.
If you qualify to participate, you will undergo some health checks, including tests for blood pressure, liver and kidney function, and other health markers. The trial is not yet recruiting participants, so there’s no immediate action needed from you, but it’s important to know that potential participants should not have a history of smoking or certain medical conditions. If you’re interested, keep an eye on updates about when the study will start recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult nonsmoker
- • Aged 18-50
- • Skin reflectance scores below 150 or above 249 using the Mexameter 18 instrument
- • Healthy on the basis of medical history
- • Systolic blood pressure \<150
- • Diastolic blood pressure \<100
- • C-reactive protein \<3.1 mg/ml
- • Liver function (AST and ALT) in normal ranges
- • kidney function (BUN) in normal ranges
- • LDL\<131
- • Blood glucose \<110
- • Not exposed to tobacco SHS.
- Exclusion Criteria:
- • Dermal skin reflectance score between 150 and 249, as measured by the Mexameter 18 instrument.
- • Positive SARS-CoV-2 antibody test
- • Age 18 \< or \> 50
- • Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.
- • Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications
- • Systolic blood pressure greater than or equal to 150
- • Diastolic blood pressure greater than or equal to 100
- • Blood glucose greater than or equal to 110
- • LDL greater than or equal to130
- • Pregnancy or breastfeeding (by urine hCG and/or history)
- • Alcohol or illicit drug dependence within the past 5 years
- • BMI \> 35 and \< 18
- • Current illicit drug use (by history or urine test)
- • More than 1 pack year smoking history
- • Ever a daily marijuana smoker
- • Smoked anything within the last 3 months
- • Unable to hold allergy or other OTC medicines
- • Occupational exposure to smoke, dusts OR fumes
- • Concurrent participation in another clinical trial
- • Unable to communicate in English
- • No social security number
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Suzaynn F Schick, PhD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported